Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company's stock worth $914,941,000 after acquiring an additional 962,644 shares in the last quarter.
Vertex Pharmaceuticals declared that its board has approved a share buyback program on Wednesday, January 31st that allows the company to repurchase $500.00 million in outstanding shares. Kanawha Capital Management Llc who had been investing in Dominion Energy for a number of months, seems to be less bullish one the $48.98B market cap company. The stock increased 1.58% or $0.62 during the last trading session, reaching $39.83. About 1.59M shares traded. (NASDAQ:ACAD) to report earnings on February, 27. It has underperformed by 17.13% the S&P500.
Suntrust Banks Inc. increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. $266,610 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Chodakewitz Jeffrey. The institutional investor held 29,075 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $4.42M, up from 3,000 at the end of the previous reported quarter. Wildcat Capital Management Llc who had been investing in Sabine Royalty Trust for a number of months, seems to be bullish on the $656.07 million market cap company. Orbimed Advisors LLC now owns 2,074,302 shares of the pharmaceutical company's stock valued at $315,377,000 after buying an additional 47,800 shares during the last quarter. During the same period in the previous year, the company earned $0.35 EPS. equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.67 earnings per share for the current fiscal year.
Recent insider trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have caught the attention of investors. It has outperformed by 28.99% the S&P500.
Heart-healthy diet may also reduce risk of depression
Cherian stopped short of saying following DASH will definitively reduce your depression risk, noting more studies are required. Depression affects about 16 million American adults every year, according to the Centers for Disease Control and Prevention .
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, January 31st. For the past 5 years, the company's revenue has grown 81.8%, while the company's earnings per share has grown 0%. VRTX's profit will be $68.55 million for 156.98 P/E if the $0.27 EPS becomes a reality. Bank of New York Mellon Corp increased its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Amp Cap Invsts Limited holds 0.11% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 130,142 shares. Therefore 87% are positive. Argus set a $194.00 price target on Vertex Pharmaceuticals and gave the company a "buy" rating in a report on Friday.
In other news, CFO Thomas Graney sold 777 shares of the company's stock in a transaction on Tuesday, January 2nd. Oppenheimer maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, July 27 with "Buy" rating. The firm has week's performance of 5.49%as it receives analyst recommendation of 1.80 on scale of 1-5. Bank of America upgraded the stock to "Buy" rating in Friday, January 5 report. Needham maintained it with "Buy" rating and $195.0 target in Thursday, October 26 report. JMP Securities initiated the stock with "Market Outperform" rating in Tuesday, October 27 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has "Buy" rating given on Tuesday, July 18 by BMO Capital Markets.
Since August 31, 2017, it had 0 insider purchases, and 43 insider sales for $118.28 million activity. Silva Paul M sold $1.71 million worth of stock or 9,883 shares. Following the transaction, the senior vice president now owns 19,525 shares of the company's stock, valued at $3,094,517.25. Arbuckle Stuart A sold 8,500 shares worth $1.39 million. With an institutional ownership near 3.9%, it carries an earnings per share ratio of -1.04. Daiwa Securities Group Inc. now owns 7,561 shares of the pharmaceutical company's stock worth $1,150,000 after buying an additional 391 shares during the period. Its down 0.50, from 1.38 in 2017Q2. It increased, as 32 investors sold VRTX shares while 151 reduced holdings. 64 funds opened positions while 129 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Vertex Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $183.79. Parnassus Invs Ca holds 7.55 million shares or 1.14% of its portfolio. Employees Retirement Association Of Colorado holds 454,468 shares or 0.5% of its portfolio. Finally, Old Mutual Global Investors UK Ltd. increased its holdings in shares of Vertex Pharmaceuticals by 0.5% in the 3rd quarter. 1,588 are held by Cannell Peter B And. The Patten Group Inc holds 1 shares with $8,000 value, down from 50 last quarter. Korea Corp invested in 114,002 shares. 22,609 were accumulated by Princeton Mgmt. Martingale Asset Management LP has invested 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The SI to PILBARA MINERALS LTD ORDINARY SHARES AU's float is 0.45%. Somerville Kurt F reported 0.05% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). $960,960 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit.
Bank Of Montreal, which manages about $34.23B and $109.19 billion US Long portfolio, upped its stake in Arrow Electrs Inc (NYSE:ARW) by 15,514 shares to 35,403 shares, valued at $2.85M in 2017Q3, according to the filing. It also reduced its holding in Meridian Bancorp Inc Md (NASDAQ:EBSB) by 25,739 shares in the quarter, leaving it with 214,261 shares, and cut its stake in Avexis Inc. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twenty-five have issued a buy rating to the stock. Therefore 78% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. The firm has "Buy" rating by Deutsche Bank given on Thursday, August 3. The rating was initiated by Oppenheimer on Thursday, December 15 with "Perform". The stock has "Hold" rating by RBC Capital Markets on Friday, August 11. Susquehanna Intl Grp Llp reported 9,604 shares. The firm earned "Overweight" rating on Monday, September 14 by Barclays Capital.